Septerna (NASDAQ:SEPN) Downgraded by Wells Fargo & Company to Equal Weight

Wells Fargo & Company lowered shares of Septerna (NASDAQ:SEPN) from an overweight rating to an equal weight rating in a report published on Tuesday, MarketBeat Ratings reports. They currently have $14.00 price objective on the stock.

Other analysts have also issued research reports about the company. JPMorgan Chase & Co. initiated coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target for the company. TD Cowen began coverage on Septerna in a report on Tuesday, November 19th. They set a “buy” rating for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $50.00 price objective on shares of Septerna in a research note on Tuesday, February 11th.

Septerna Price Performance

NASDAQ:SEPN opened at $6.87 on Tuesday. The firm’s 50-day moving average is $18.82. Septerna has a 52-week low of $4.17 and a 52-week high of $28.99.

Hedge Funds Weigh In On Septerna

Hedge funds have recently made changes to their positions in the business. Avoro Capital Advisors LLC bought a new position in shares of Septerna in the fourth quarter worth about $25,419,000. TRV GP V LLC bought a new position in Septerna during the fourth quarter valued at approximately $142,337,000. TRV GP VI LLC bought a new position in Septerna during the fourth quarter valued at approximately $72,191,000. Vanguard Group Inc. bought a new position in Septerna during the fourth quarter valued at approximately $22,557,000. Finally, Corebridge Financial Inc. bought a new position in Septerna during the fourth quarter valued at approximately $212,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.